Shore Capital Reaffirms Buy Rating for hVIVO (LON:HVO)

hVIVO (LON:HVO)‘s stock had its “buy” rating reissued by Shore Capital in a research note issued to investors on Thursday, Marketbeat Ratings reports.

hVIVO Stock Performance

Shares of HVO opened at GBX 15.81 ($0.21) on Thursday. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock has a market cap of £111.87 million, a P/E ratio of 6.52 and a beta of 0.97. The business’s 50 day moving average price is GBX 16.07 and its 200-day moving average price is GBX 20.79. hVIVO has a 52 week low of GBX 12.60 ($0.16) and a 52 week high of GBX 31 ($0.41).

hVIVO (LON:HVO) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Equities research analysts anticipate that hVIVO will post 1.5492958 earnings per share for the current fiscal year.

Insider Buying and Selling at hVIVO

In related news, insider Yamin Mo’ Khan sold 3,062,246 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.22), for a total value of £520,581.82 ($681,389.82). 14.03% of the stock is owned by company insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.